SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques by Garrido, C. et al.
Cite as: C. Garrido et al., Sci. Immunol. 
10.1126/sciimmunol.abj3684 (2021). 
RESEARCH ARTICLES
First release: 15 June2021  immunology.sciencemag.org  (Page numbers not final at time of first release) 1 
INTRODUCTION 
Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has infected hundreds of millions of people worldwide 
and caused over 3.5 million deaths since its emergence in 
2019. The need for safe and effective measures to limit trans-
mission and mitigate public health and socioeconomic im-
pacts of SARS-CoV-2 infection has prompted unprecedented 
vaccine development of promising candidates. In fact two 
messenger RNA (mRNA) vaccines, mRNA-1273 (Moderna) (1, 
2) and BNT162b2 (Pfizer-BioNTech) (3, 4), are authorized for
emergency use in the United States to prevent SARS-CoV-2 
infection in adults. Both are safe, and induce neutralizing an-
tibodies and up to 95% protection from disease. Additionally, 
the Oxford/AstraZeneca adenovirus-based ChAdOx1 nCoV-19 
(AZD1222) (5), the Johnson & Johnson Ad26.COV2.S vaccine 
(JNJ-78436735) (6), and the first protein-based SARS-CoV-2 
vaccine, Novavax NVX-CoV2373, adjuvanted with saponin-
based Matrix-M (7, 8), are approved for use in human adults. 
Ethical and safety risks warrant a careful evaluation of 
novel vaccines in the pediatric population. Generally, vaccine 
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The inclusion of infants in the SARS-CoV-2 vaccine roll-out is important to prevent severe complications of 
pediatric SARS-CoV-2 infections and to limit transmission and could possibly be implemented via the global 
pediatric vaccine schedule. However, age-dependent differences in immune function require careful 
evaluation of novel vaccines in the pediatric population. Toward this goal, we assessed the safety and 
immunogenicity of two SARS-CoV-2 vaccines. Two groups of 8 infant rhesus macaques (RMs) were 
immunized intramuscularly at weeks 0 and 4 with stabilized prefusion SARS-CoV-2 S-2P spike (S) protein 
encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or the purified S protein mixed with 3M-
052, a synthetic TLR7/8 agonist in a squalene emulsion (Protein+3M-052-SE). Neither vaccine induced 
adverse effects. Both vaccines elicited high magnitude IgG binding to RBD, N terminus domain, S1, and S2, 
ACE2 blocking activity, and high neutralizing antibody titers, all peaking at week 6. S-specific memory B 
cells were detected by week 4 and S-specific T cell responses were dominated by the production of IL-17, 
IFN-γ, or TNF-α. Antibody and cellular responses were stable through week 22. The immune responses for
the mRNA-LNP vaccine were of a similar magnitude to those elicited by the Moderna mRNA-1273 vaccine in 
adults. The S-2P mRNA-LNP and Protein-3M-052-SE vaccines were well-tolerated and highly immunogenic 
in infant RMs, providing proof-of concept for a pediatric SARS-CoV-2 vaccine with the potential for durable 
immunity that might decrease the transmission of SARS-CoV-2 and mitigate the ongoing health and 
socioeconomic impacts of COVID-19. 
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testing is performed in an age de-escalation manner, starting 
with adults, followed by adolescents, with children and in-
fants being last (9). The BNT162b2 mRNA vaccine is now ap-
proved for use in adolescents 12 years and older, with trials 
for children age 6 to 12 already underway (NCT04816643). 
The Moderna mRNA-1273 vaccine is close to approval for use 
in children 12 years and older. Importantly, Moderna and 
Pfizer both have initiated clinical trials that will include in-
fant as young as 6 months (NCT04796896 and NCT04816643, 
respectively). The important epidemiologic impact of pediat-
ric SARS-CoV-2 vaccination lies in limiting transmission and 
ease of implementation via the global pediatric vaccine 
schedule. 
Early in the pandemic, vaccines to prevent SARS-CoV-2 
infection in children were not a priority because of apparent 
low infection and disease rates. In most children, SARS-CoV-
2 infection causes only relatively mild disease. Nonetheless, 
some children develop severe symptoms, such as the multi-
system inflammatory syndrome, requiring hospitalization 
and sometimes leading to death (10–14). Importantly, severe 
complications of SARS-CoV-2 infection disproportionally af-
fect children of ethnic and racial minorities, amplifying 
health disparities in pediatric care in the United States (15, 
16). While children may transmit less efficiently than adults, 
virus transmission by children, even when asymptomatic, is 
documented (17, 18). Therefore, children have the propensity 
to become a major viral reservoir if pediatric vaccination 
stalls. The latter potential is especially concerning because 
new SARS-CoV-2 variants with increased transmission rates 
are emerging and SARS-CoV-2 has become more likely to per-
sist on the population level. Although data are scarce, in-
creased pediatric infection rates that appeared to coincide 
with the emergence of new variants, have been reported (19, 
20). There is ample precedence for the beneficial impact of 
pediatric vaccination. 
Children have suffered from the SARS-CoV-2 pandemic in 
many additional ways. We will not know the exact burden of 
the loss of education due to closure of schools and virtual 
learning until years from now. School closure meant that 
many children were deprived of social interactions, a food 
source, and a safe place (21–23). There has been an epidemic 
rise in depression and anxiety in children, and the long-term 
mental health burden of these diverse factors is difficult to 
assess. School closure also translated to loss of work for many 
parents, especially women. A pediatric SARS-CoV-2 vaccine 
could mitigate at least some of these societal costs. 
These combined data emphasize the importance of get-
ting children vaccinated for SARS-CoV-2 (24–27). However, 
vaccine-elicited immunity differs between adults and infants 
(reviewed in (28)), with impaired responses to carbohydrate 
antigen vaccines (29), but higher magnitude humoral im-
munity to subunit-based vaccines (e.g., Hepatitis B) (30) early 
in life. Thus, the evaluation of SARS-CoV-2 vaccine immuno-
genicity in infants is critical. Toward this goal, the present 
study was designed to evaluate the safety and immunogenic-
ity of stabilized prefusion SARS-CoV-2 Spike vaccines deliv-
ered as lipid nanoparticle-encapsulated mRNA or an 
adjuvanted subunit protein in a relevant animal model. Non-
human primates (NHP), including rhesus macaques (RMs), 
are an important model for SARS-CoV-2 studies given the 
similarities to humans in pathogenesis and host immune re-
sponses (31). Indeed, results from adult NHP studies of hu-
man SARS-CoV-2 vaccine candidates (32–35) strongly 
correlate with clinical trial outcomes, and infant NHP models 
of other infectious diseases closely mirror responses in hu-
man infants (36, 37). Data by our group support that infant 
vaccine-elicited antibody against HIV envelope can be of 
higher magnitude than those elicited by adults, (38) We also 
demonstrated that infant RMs generate high magnitude an-
tibody responses to HIV Env protein vaccination, (39) and 
that peripheral and mucosal B cell responses can be boosted 
later in life. (40) 
The primary goal of the current study was to inform hu-
man pediatric trials and aid in fast-tracking pediatric SARS-
CoV-2 vaccines for inclusion in the early life vaccine schedule 
by providing proof-of-concept that the two SARS-CoV-2 vac-
cines are safe and immunogenic in infant RMs. A secondary 
goal of our study was to assess the durability of vaccine-in-
duced immune responses as data are lacking on this. Despite 
some caveats inherent to comparisons between studies with 
differences in study design, the immune responses in infant 
RMs in response to the two SARS-CoV-2 vaccines tested ap-
pear to be within the range of vaccine-induced immune re-
sponses reported for adult RMs (32, 41) and humans (2, 42, 
43). 
RESULTS 
Study design and vaccine safety 
Infant RMs at a median age of 2.2 months, corresponding 
to 9-month old human infants (44), were immunized at 
weeks 0 and 4 with 30 μg mRNA encoding stabilized pre-
fusion SARS-CoV-2 S-2P protein in lipid nanoparticles 
(mRNA-LNP; n=8) or with 15 μg S-2P mixed with 3M-052-SE,
a TLR7/8 agonist in a stable emulsion (Protein+3M-052-SE; 
n=8) (Fig. 1, Table 1). Blood and saliva were collected before 
vaccination (week 0), 4 weeks after the first dose of the vac-
cine (week 4), 2 weeks after the vaccine boost (week 6), and 
at weeks 8, 14, 18 and 22. Lymph nodes were sampled at week 
6 (Fig. 1). 
Animals were monitored daily for adverse events. No local 
injection site or systemic adverse reactions were observed. 
Animals had normal blood metrics (Supplementary Table S1). 
Importantly, the animals gained weight consistent with ade-
quate fluid and nutrition uptake and with normal infant 
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growth (Supplementary Fig. S1) (45). A major safety concern 
in the implementation of a pediatric SARS-CoV-2 vaccine 
stems from adverse events observed with an earlier Respira-
tory Syncytial Virus vaccine, that were partially attributed to 
T helper 2 (TH2)-biased responses (46, 47). We therefore 
tested plasma samples prior to or following immunization for 
changes in TH2 (IL-4, IL-13) or TH1 (IL-2, IFN-γ) cytokines
(Fig. S2). Animal RM3 of the protein group (Table 1) tested 
positive for all cytokines at both time points; cytokines were 
also detected in the mRNA-LNP recipient RM11 at week 0, 
but fell below the limit of quantification by week 6. In gen-
eral, neither vaccine appeared to induce systemic TH2 or TH1 
responses (Fig. S2), further supporting a good safety profile. 
Infant plasma and salivary antibody responses to SARS-
CoV-2 vaccination 
Plasma IgG binding to the S-2P protein was observed after 
the vaccine prime for both mRNA-LNP and Protein+3M-052-
SE vaccines and increased after the second immunization 
(Fig. 2). Although antibody levels dropped by week 8, there 
was only a slight decline of S-2P-specific IgG from week 8 to 
week 22 for mRNA-LNP (median AUC and 95% confidence 
intervals: 7.0 [6.2, 8.3] to 5.4 [4.2, 7.7]) or Protein+3M-052-SE 
(11.0 [9.5, 11.7] to 9.4 [8.6, 10.5] vaccinees (Fig. 2A). Longitu-
dinal S-specific plasma IgG data reported as EC50 or endpoint 
dilution titers followed a similar trend (Fig. S3). As the D614G 
virus variant had become dominant in the USA at the study 
initiation, we confirmed that IgG binding to S-2P D614G was 
similar to that of D614 at weeks 6 and 14 (Fig. S4). Plasma 
IgG antibodies were directed against multiple spike domains 
and persisted throughout the study, with robust binding to 
Spike regions 1 and 2 (S1, S2), Receptor binding domain 
(RBD), and N-terminal domain (NTD) (Fig. 2B). RBD-specific 
salivary IgG from mRNA-LNP recipients peaked at a median 
of 16.6 ng RBD-specific IgG per μg of total IgG at week 6 (Fig.
2C). In the Protein+3M-052-SE group, median salivary RBD-
specific IgG peaked at 98.2 ng/μg IgG after the second vac-
cination and remained detectable throughout the study (Fig. 
2C). Saliva RBD-specific IgA responses were much lower (Fig. 
S5). Spike-specific IgM and IgA in plasma were low or unde-
tectable (Fig. S5). In the mRNA-LNP group, IgM increased 
through week 14, but the absorbance readings for IgM were 
considered low, measured at a 1:10 sample dilution (Fig. S5). 
Function of vaccine-induced plasma antibodies 
We next evaluated the capacity of plasma antibodies to 
block entry of SARS-CoV-2 into human cells using a RBD-
ACE2 blocking assay at 1:10 and 1:40 plasma dilutions. Anti-
bodies elicited by the mRNA-LNP vaccine completely blocked 
RBD-ACE2 interaction at week 6 at 1:10 and 1:40 dilutions. 
Greater than 80% blocking was achieved at 1:10 dilution until 
week 14, dropping for some animals after week 18 (Fig. 3A). 
The Protein+3M-052-SE vaccine induced antibodies that me-
diated 100% RBD-ACE2 blocking after the second 
immunization (Fig. 3A). At a 1:40 plasma dilution, the RBD-
ACE2 blocking function decreased over time, but was still de-
tectable at week 22 (Fig. S6). 
Neutralizing antibodies, measured by a pseudovirus as-
say, were detected in all mRNA-LNP vaccinated animals and 
in 7 of 8 animals of the Protein+3M-052-SE group after the 
first vaccination, and further increased after the boost. Peak 
median infectious dose 80 (ID80) titers were observed at week 
6 and reached 1,179 in mRNA-LNP and 13,687 in Protein+3M-
052-SE animals (Fig. 3B). Similar to S-specific plasma IgG lev-
els, and consistent with antibody kinetics after vaccination,
median ID80 neutralization titers decreased following the
peak response. Neutralization titers appeared to stabilize
around week 18, and median ID80 titers at week 22 remained
2.6-fold or 14.2-fold higher in the mRNA-LNP or Protein+3M-
052-SE group, respectively, than after the first vaccination
(week 4) (Fig. 3B). Although definite immune correlates of
protection after vaccination still need to be conclusively de-
termined, we modeled a bi-phasic antibody decline for both
vaccines to reach a putative protective neutralizing Ab titer,
estimated at a reciprocal dilution of 100 (41, 48). Applying
this assumption, mRNA-LNP vaccinees maintained a protec-
tive neutralizing Ab titer for approximately 46 weeks and pro-
tein vaccine recipients for approximately 74 weeks (Fig. S7).
Neutralizing antibody kinetics in the whole virus neutral-
ization assay followed a similar trend (Fig. 3C). The animal 
(RM 1) of the Protein+3M-052-SE group that did not have de-
tectable neutralizing antibodies by week 4 in the pseudovirus 
neutralization assay, also only had a slight increase in the 
ID80 neutralizing antibody titer using the live virus assay 
(week 0: 129; week 4: 223). Overall, ID50 and ID80 titers of 
both assays strongly correlated with each other (r = 0.644, 
p=0.008 or r=0.785, p=0.0005, respectively Fig. S8). However, 
infant RMs already had low titer neutralizing antibodies at 
day 0 when we applied the whole virion neutralization assay 
(Fig. 3C). As infants could have passively acquired antibodies 
from their mothers, we measured neutralizing antibodies in 
the sera of their unvaccinated dams. Although detectable, 
neutralizing antibody titers in dams did not correlate to in-
fant neutralization titers before (ID80: r=0.011, p=0.96) or af-
ter vaccination (ID80: r=-0.056, p=0.83) (Fig. S9), most likely 
because infant rhesus macaques were already 2 months old 
at study initiation and maternal antibodies had waned. 
Vaccine-elicited B cell responses 
Consistent with the induction of plasma S-specific IgG, S-
specific memory CD27+ B cell were detectable in the blood of 
both vaccine groups at week 4 and peaked at week 6 (median: 
0.75% mRNA-LNP; 3.12%, Protein+3M-052-SE). At week 14, 
median memory B cell frequencies were lower (0.19% and 
0.13% in mRNA-LNP or Protein+3M-052-SE vaccinees, re-
spectively), but did not differ from those at week 4 (Fig. 4A). 
In lymph nodes (LNs), we measured total germinal center 
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(GC) B cells and memory B cells and then determined the 
number of S-specific memory B cells (Fig. 4B). In both vaccine 
groups robust memory B cell populations (median 3.78% 
mRNA-LNP and 1.96% Protein-3M-052) were present (Fig. 
4B). Induction of S-specific B cells was confirmed by as-
sessing S-specific antibody secreting cells (ASC). In the blood, 
peak responses were observed at week 6 in the mRNA-LNP 
group (median: 154 ASC/million cells) and at week 8 in the 
Protein+3M-052-SE group (median: 85 ASC/106 cells) (Fig. 
4C). In draining LNs, mRNA-LNP and Protein+3M-052-SE 
vaccinees had median 6 or 952 ASC/106 cells, respectively 
(Fig. 4D). 
In addition, we analyzed LN samples for canonical T fol-
licular helper (TFH) (CD185/CXCR5+CD279/PD-1+) cells and 
for IL-4 or IL-21 producing CD4+ T cells that support GC B 
cell differentiation (Fig. 5A). SEB-activated TFH 
(CD185+CD279+CD134+CD137+) (49) (Fig. 5B) were catego-
rized into TFH1, TFH2 and TFH17 subsets based on expression of 
CXCR3/CD183 and/or CCR6/CD196 (50) (Fig. 5C). We found 
no correlations between bcl6+Ki67+ GC B cells or bcl6+TFH 
(Fig. S10A, B), potentially because we assessed these cell pop-
ulations in an antigen non-specific manner. However, 
CD4+IL21+ cells correlated with pseudovirus neutralizing an-
tibody ID50 at week 6 (r=0.749, p=0.001) (Fig. S10C). 
Spike protein-specific T cell responses 
In some animals, S-specific CD4+ T cell responses in 
PBMC were detected as early as week 4, with all animals pro-
ducing at least a single cytokine by week 6 (Fig. 6; see Fig. 
S16 for gating strategies). At week 14, CD4+ T cells of mRNA-
LNP vaccinated animals produced IL-2, IFN-γ, IL-17, and
TNF-α responses (Fig. 6D), whereas IL-17 and IFN-γ CD4+ T
cell responses dominated in Protein+3M-052-SE vaccinees 
(Fig. 6D). Multifunctional CD4+ T cells co-produced IL-17 and 
IFN-γ (Fig. S11), suggesting a TH1/TH17 biased response. Alt-
hough we did not measure IL-4 production, and limited cell 
numbers - typical for pediatric samples - prevented us from 
repeating the assay, it should be reiterated that neither of the 
vaccines caused a rise in systemic TH2 cytokines (Fig. S2). S-
specific peripheral blood CD8+ T cell responses appeared less 
robust than CD4+ T cell responses and only single-cytokine 
positive were elicited, but all animals produced at least a sin-
gle cytokine in response to antigen stimulation (Fig. S12). In 
LNs, 6 of 8 and 8 of 8 animals in the mRNA-LNP or Pro-
tein+3M-052-SE group had S-specific CD4+ T cell responses, 
respectively. In addition, 8 of 8 mRNA-LNP vaccinees and 7 
of 8 Protein+3M-052-SE vaccinees mounted S-specific CD8+ 
T cell responses in LN at week 6 (Fig. S13). 
Overall, these data suggested that infant RMs can mount 
robust antibody, including high titer neutralizing and ACE2 
blocking antibodies, and T cell responses to SARS-CoV-2 vac-
cines. Vaccine-induced immune responses persisted for 22 
weeks or 18 weeks after the first and second vaccine dose, 
respectively, results consistent with vaccine-induced 
memory. 
DISCUSSION 
Several SARS-CoV-2 vaccines have demonstrated safety, 
immunogenicity and protection in animal studies (8, 32, 51, 
52) and in clinical trials with human adults (1, 5, 6), and sub-
sequently received authorization for emergency use in hu-
man adults. Considering the enormous health and
socioeconomic impact of the SARS-CoV-2 pandemic on all
age groups, clinical trials to test the safety of SARS-CoV-2 vac-
cines in adolescents and children have been initiated. In fact,
the Pfizer-BioNTech mRNA vaccine is already approved for
adolescents 12 years and older, Moderna’s vaccine
(NCT04796896) has recently been reported to be 96% effec-
tive in adolescents ages 12-17, and Novavax (NCT04611802)
has an ongoing trial to test its vaccine this age group. How-
ever, data regarding the safety and immunogenicity of SARS-
CoV-2 vaccines in young infants are still lacking.
We reasoned that validating safety and immunogenicity 
of SARS-CoV-2 vaccines in infant rhesus macaques would 
provide beneficial information supporting the initiation of 
pediatric vaccine trials down to 6 months of age. Here, we 
present preclinical data demonstrating that infant rhesus 
macaques develop strong, durable humoral and cellular re-
sponses in the absence of adverse events following vaccina-
tion with a preclinical version of the Moderna mRNA-1273 
vaccine or with stabilized prefusion S-2P SARS-CoV-2 protein 
mixed with 3M-052-SE, a TLR7/8 agonist in squalene emul-
sion. We selected the mRNA-LNP vaccine expressing S-2P be-
cause at the initiation of the study mRNA vaccines were 
quickly progressing through phase 3 clinical studies toward 
approval for human use, with EUA approval in the US in late 
2020. We therefore considered this to be the class of vaccines 
most likely to be among the first vaccines to eventually pro-
gress for testing in the pediatric population. The 3M-052-SE 
adjuvant was chosen for the S-2P protein vaccine because this 
adjuvant has proven effective in eliciting high magnitude an-
tibody responses to other vaccines in infant rhesus macaques 
(39, 53). 
We assessed infant vaccine-induced immune responses 
over 22 weeks, analogous to adult clinical trials (1, 2). Both 
vaccines elicited plasma antibodies dominated by IgG and 
recognized all Spike protein domains. Binding antibodies 
persisted throughout the study in all animals of both groups. 
Interestingly, RBD-specific IgG was also detected in saliva, 
especially in animals of the protein vaccine group, and re-
mained detectable throughout the study, similar to what has 
been observed after human natural infection (54). Moreover, 
7 of 8 Protein+3M-052-SE vaccinated animals had RBD-
specific IgA after the 2nd immunization. The overall low in-
duction of S-2P- and RBD-specific IgA by vaccination might 
be attributed to the delayed development of mucosal IgA 
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compared to IgG responses in human and rhesus infants (55–
57). Vaccine-induced neutralizing antibody kinetics paral-
leled those observed for plasma binding antibodies and per-
sisted for the duration of the study. At week 22, 18 weeks after 
the 2nd dose, median ID50 titers in the pseudovirus assay still 
exceeded 103 for the protein vaccine group and 102 for the 
mRNA group. 
The immune correlates of protection against SARS-CoV-2 
infection and disease still need to be conclusively determined 
(58, 59). To address this question, McMahan et al. (48) adop-
tively transferred plasma IgG from adult SARS-CoV-2 conva-
lescent rhesus macaques and determined that a S protein-
specific reciprocal endpoint dilution ELISA titer of 400 and 
pseudovirus neutralizing antibody (ID50) titers of approxi-
mately 50 can protect adult rhesus macaques against com-
bined intratracheal and intranasal SARS-CoV-2 challenge 
(48). Applying these criteria to our results, we hypothesized 
that pediatric vaccination could provide protection against 
SARS-CoV-2 infection. However, we purposely decided to de-
lay the challenge of our animals until one year post vaccina-
tion to better determine the long-term persistence of vaccine-
induced neutralizing antibodies, which is especially im-
portant to a pediatric vaccine for a disease that affects all age 
groups. These data will be reported in a follow up study. Fur-
thermore, the drop in ACE2-blocking function in some ani-
mals of the mRNA-LNP group raises the possibility that some 
of our vaccinated animals might develop disease, whereas 
others would be protected. Such an outcome would allow us 
to define immune correlates of protection, including the pro-
tective titer of neutralizing antibodies against infection and 
from severe disease, but also enable us to assess the contri-
bution of other vaccine-induced immune responses (e.g., T 
cell responses) to protection. 
Early life immunity is associated with TH2-biased T cell 
responses (60), and TH2 responses have been linked to vac-
cine-associated enhanced respiratory disease in the context 
of protein or inactivated virus vaccines (6, 61, 62). We ob-
served a TH1/ TH17-skewed cytokine profile in circulating S-
specific T cells. Our finding of peak S-specific T cell responses 
10 weeks post-boost are not unexpected. T cell reactivity in 
convalescent COVID-19 patients have augmented frequency 
and potency 100 days post-recovery, even as S-specific anti-
body waned (63). Indeed, ~93% of “exposed asymptomatic” 
patients possess SARS-CoV-2-specific memory T cell subsets 
in the absence of seroconversion (64). Higher TFH2 frequen-
cies compared to TFH1 do not necessarily imply a TFH2-bias as 
TFH17 cells were also detected, and TFH were not assessed for 
antigen specificity. We found no evidence of systemic TH2 cy-
tokines prior to or following immunization in either vaccine 
group, corroborating previous findings in adult macaques 
(32) and adult humans (42) that also demonstrated low level
or absent TH2-mediated responses. IL-4 and IL-21 producing
TFH are required for the induction of GC B cells in LNs (65), 
indispensable for B cell and antibody affinity maturation, and 
GC reactions are important for positive outcomes in COVID-
19 patients (65). Indeed, the persistence of antibody was par-
alleled by sustained S-specific B cell responses. The induction 
and persistence of S-specific B cell clones described here may 
be key to protection against re-infection (66). In the current 
study, S-specific CD8+ T cell responses were lower compared 
to CD4+ T cell responses in the same animals. As CD8+ T cell 
response play an important role in the control of virus repli-
cation, future studies need to determine the contribution of 
vaccine-induced cytotoxic T cell responses to protection 
against SARS-CoV-2 infection. 
Overall, the adjuvanted protein vaccine seemed to elicit 
stronger immune responses compared to the mRNA vaccine. 
We can only speculate why the vaccine-induced immune re-
sponses were different between the Protein+3M-052-SE and 
the mRNA-LNP regimens. First, we do not know the exact 
amount of protein expressed by the mRNA-LNP vaccine in 
vivo. Second, we and others have previously demonstrated 
that the TLR7-8-based adjuvant 3M-052 is highly effective in 
enhancing antibody responses in the rhesus macaque model 
(39, 53). TLR7/8 agonists, in contrast to most other TLR ago-
nists, promote potent IL-12 responses by antigen-presenting 
cells (67–69) that in neonates and young infants are normally 
biased toward IL-23 production (70). Therefore, the priming 
of T helper cells and antibody responses is assumed to be im-
proved by the inclusion of the 3M-052-SE adjuvant. Nonethe-
less, the data do not imply that the mRNA-LNP vaccine was 
less successful in inducing immune responses compared to 
responses observed in human clinical trials or in adult NHP. 
In fact, S-specific T and B cell responses to the mRNA-LNP 
vaccine persisted throughout the study period. 
It is difficult to directly compare the results of the current 
study with published data from human clinical trials or from 
adult NHP studies. We are not aware of published data using 
the Protein+3M-052-SE vaccine for SARS-CoV-2 in NHP. Re-
sults from human and NHP studies with the mRNA-1273 vac-
cine are listed in Table 2 (2, 32, 41–43). It should be noted 
that the various studies differed in their design. Keeping this 
caveat in mind, the magnitude, quality, and durability of the 
mRNA-LNP vaccine-induced responses in infant macaques 
appear to be within the range of those observed in adult NHP 
and human studies. 
We demonstrated that infant rhesus macaques mount 
strong and durable responses to mRNA-LNP and protein-
based SARS-CoV-2 vaccines that were comparable to adults 
without adverse reactions. These promising results endorse 
clinical translation of SARS-CoV-2 vaccines to early life pop-
ulations. Even when the majority of adults and adolescents 
have been vaccinated and herd immunity is achieved, glob-
ally about 140 million infants are born each year (71) and they 
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will be naïve and susceptible to SARS-CoV-2 once passively 
transferred maternal antibodies wane. Being cautiously opti-
mistic, a multivalent SARS-CoV-2 vaccine effective against 
major circulating viral variants appears feasible and could 
become part of the standard pediatric vaccine program. 
MATERIALS and METHODS 
Study Design 
The objective of this study was to provide proof-of-concept 
that young infants (<1 year) could mount functional and du-
rable neutralizing antibody responses and T cell responses to 
SARS-CoV-2 vaccination. Considering the extent of the SARS-
CoV-2 pandemic, the rapid emergence of new viral variants 
with increased transmission rates with yet unknown impact 
on pediatric infections, our goal was to inform human SARS-
CoV-2 vaccine age de-escalation studies to fast-track vaccine 
implementation in the pediatric population. Utilizing the 
highly relevant infant rhesus macaque model, we tested the 
safety and immunogenicity of a preclinical version of the 
mRNA 1273 SARS-CoV-2 vaccine (n=8) and a stabilized pre-
fusion SARS-CoV-2 S-2P spike (S) protein vaccine mixed with 
the 3M-052 adjuvant in stable emulsion (n=8) (Fig. 1; Table 
1). S-specific cellular responses and antibody responses were 
monitored for 22 weeks. 
Animals 
Infant male (n=8) and female (n=8) rhesus macaques 
(Macaca mulatta; RM) of Indian-origin from the California 
National Primate Research Center (CNPRC, Davis, CA) breed-
ing colony (negative for type D retrovirus, simian immunode-
ficiency virus, simian lymphocyte tropic virus type 1 and 
SARS-CoV-2), were enrolled at a median age of 2.2 months 
and randomly assigned into two groups (Table 1). Infants 
were housed with their dams until about 6 months of age, 
and then weaned and pair-housed. Animal care was in com-
pliance with the “Guide for Care and Use of Laboratory Ani-
mals” by the Institute for Laboratory Animal Research. 
Animal procedures were approved by the UC Davis Institu-
tional Animal Care and Use Committee prior to study initia-
tion. All procedures were performed under anesthesia 
(ketamine, 10 mg/kg body weight, intramuscularly [IM]). 
Blood, saliva and lymph nodes (LN) were collected and pro-
cessed as described (72). 
Preparation of the SARS CoV2 Spike protein 
The CoV2 Spike (73) (2019-nCoV) protein was transiently 
expressed in Freestyle HEK293 cells (Thermo Scientific) by 
first diluting the plasmid in Opti-MEM-1 (Gibco) medium; 
0.8mg of plasmid in 25mL of Opti-MEM-1 for each liter of 
cells transfected and sterile filtered using a 0.22 μm filter. 1
mL of 293fectin (Gibco) was diluted in 25 mL of Opti-MEM-1 
and allowed to incubate at room temperature for 5 ± 1 min. 
The plasmid and the 293fectin mixtures were combined and 
swirled to mix, then incubated at room temperature for 25 ± 
5 min. During the incubation, the Freestyle HEK293 cells 
were diluted to 1.25×106 cells/ mL in a 2-liter Corning flask. 
At the end of the 25 ± 5 min incubation of the 293fectin and 
plasmid mixtures, 50mL of the transfection mixture was 
added to each flask of diluted cells with gentle agitation of 
the flask during addition. The cell + transfection mixture was 
then split between two 2-liter Corning flasks for a final vol-
ume of approximately 500mL each and placed on a platform 
shaker in a humidified incubator at 37°C with 8% CO2. The 
shaker speed was set to 120rpm and the flasks allowed to in-
cubate for 6 days. At the end of the 6-day incubation, the 
flasks containing the transfected cells were removed from the 
incubator and the contents of the flasks were aseptically 
transferred to 500mL Corning centrifuge tubes. The superna-
tant was clarified by centrifugation and subsequently filtered 
using a 0.8μm filter bottle system. Keeping the clarified and
filtered supernatant on ice, the supernatant was concentrated 
using a Sartorius Vivaflow 200 30kDa TFF system. In prepa-
ration for the purification of the CoV2 Spike protein, 4mL of 
Strep-Tactin Resin (iba Life Science) was placed in a conical 
tube. The concentrated supernatant was transferred to the 
conical tube containing the Strep-Tactin resin and allowed to 
bind with gentle agitation. The supernatant and resin were 
then transferred to a polypropylene column for gravity-flow 
chromatography (BioRad). Once the resin had settled in the 
column the resin was washed and the protein eluted follow-
ing instructions supplied by the vendor (iba Life Science). The 
eluate was buffer-exchanged into 2mM Tris and 200mM So-
dium Chloride storage buffer using Millipore Centrifugal fil-
ters. The resulting material was finally filtered through a 
0.2um syringe filter (Pall) and stored in storage buffer. Addi-
tional purification by size exclusion chromatography over a 
Superose 6 column was performed to increase purity. 
Vaccines 
The SARS-CoV-2 stabilized prefusion Spike (S-2P) mRNA-
LNP vaccine was provided by Moderna, Inc. and the Vaccine 
Research Center (NIH) provided the S-2P protein. The vac-
cine regimen and specimen collection are outlined in Fig. 1. 
In humans, the dose of the Moderna mRNA-1273 vaccine is 
100 μg. However, even a 25 μg dose has proven immunogenic
and was associated with fewer side effects compared to the 
100 μg in older adults (42). In adult RMs, a 10 μg dose regi-
men induced significantly lower neutralizing antibody re-
sponses than the 100 μg vaccine (32). Thus, balancing
immunogenicity and safety, we decided to immunize infant 
RMs in the mRNA-LNP vaccine group IM at weeks 0 (quad-
riceps) and 4 (biceps) with 30 μg mRNA encoding S-P2 pro-
tein in lipid nanoparticles (mRNA-LNP), administered in 0.1 
mL phosphate-buffered saline. Note that the vaccine was 
stored at -80°C until just prior to the immunization. Infant 
RMs in the protein vaccine group were injected IM with15 μg
S-2P protein mixed with 3M-052-SE, an adjuvant formulation
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consisting of 10 μg of the synthetic TLR7/8 agonist 3M-052 in
a 2% v/v squalene-in-water emulsion (Protein+3M-052-SE) in 
0.5 mL divided across the left and right quadriceps (week 0) 
or biceps (week 4). 
Plasma IgG ELISA 
IgG binding to the stabilized SARS-CoV-2 spike protein S-
2P with or without the D614G mutation was measured in 
plasma using enzyme-linked immunosorbent assay (ELISA) 
as previously described (74). 384-well plates were coated 
overnight with 2 ug/mL of spike protein produced by the Pro-
tein Production Facility (PPF) at the Duke Human Vaccine 
Institute. Plates were then blocked with assay diluent (phos-
phate-buffered saline containing 4% whey, 15% normal goat 
serum, and 0.5% Tween 20). 10 serial 4-fold dilutions of 
plasma starting at 1:40 were added to the plates and incu-
bated for 1 hour, followed by detection with a horseradish pe-
roxidase (HRP)-conjugated antibody mouse anti-monkey IgG 
(Southern Biotech). The plates were developed by using an 
ABTS-2 [2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid)] 
peroxidase substrate system (KPL) and absorbance was read 
at 450 nM with a Spectramax Microplate Reader (Molecular 
Devices). Results were calculated as area under the curve 
(AUC) and EC50 values. AUC values were calculated using the 
Trapezoidal rule. EC50 values were calculated by fitting a 4-
parameter logistic function using nonlinear regression. 
Pooled Non-Human Primate Convalescent Serum to SARS-
CoV-2 (BEI Resources NR-52401) was used in all assays to en-
sure inter-assay reproducibility, but standard curves were not 
developed given the lack of a rhesus macaque-specific IgG re-
agent of known concentration. IgM and IgA binding to S-2P 
was measured in a single 1:10 diluted plasma sample follow-
ing the same ELISA protocol but using as detection antibody 
anti-Human IgM HRP (Jackson Immunoresearch) for IgM 
detection and 10F12-biotin (NHP Reagent Resource) with 
Streptavidin-HRP (Pierce) for IgA detection. Results are ex-
pressed as OD450. 
Measurement of Salivary S-specific IgG and IgA 
Saliva was collected with absorbent Merocel sponges 
(Beaver Visitec) by placing a sponge between the cheek and 
gum in the back of the mouth for 5 min. Secretions were 
eluted by centrifugation at 18,000 g and 4°C after addition of 
50μl of PBS containing protease inhibitors (75), 1% TritonX-
100, 1% BSA, 0.05% azide, and 0.05% Tween-20 to sponges. A 
customized binding antigen multiplex assay (BAMA) was 
used to measure IgG or IgA antibodies to SARS CoV-2 recom-
binant receptor binding domain protein (RBD; generously 
provided by Dr. Wrammert, Emory University, Atlanta, GA) 
and S2 extracellular domain (SinoBiologicals #40590-V08B, 
Wayne, PA). Briefly, proteins were dialyzed in PBS and con-
jugated to Bioplex Pro carboxylated magnetic beads (Bio-Rad, 
Hercules, CA) using N-hydroxysulfosuccinimide and ethyl-
carbodiimide as described (76). Serial dilutions of standard 
and centrifuged salivary secretions in PBS containing 1% Tri-
tonX-100, 1% BSA, 0.05% azide, and 0.05% Tween-20 were 
mixed with RBD+S2 beads overnight at 1100rpm and 4°C us-
ing a plate mixer. The IgG standard was a cocktail of anti-S1 
RBD (Genscript #HC2001) and anti-S2 (SinoBiologicals 
#40590-D001) humanized IgG monoclonal antibodies. The 
standard for IgA assays was a pooled serum from infected 
rhesus macaques (77) that had been calibrated relative to the 
previously mentioned monoclonal antibodies. The following 
day, beads were alternately washed using a Bio-Rad BioPlex 
wash station and treated for 30min with 2μg/ml biotinylated
affinity-purified goat antibody to human γ chain (Southern-
Biotech Associates, Birmingham, AL) or clone IgA5-3B mouse 
anti-monkey IgA (Bio-Rad) followed by 1/400 avidin-phyco-
erythrin (Southern Biotechnology Associates). A Bio-Rad Bi-
oplex 200 and BioManager software were used to measure 
fluorescent intensity and construct standard curves for inter-
polation of antibody concentrations in test samples. Concen-
trations of antibody measured in a Luminex-based binding 
antibody multiplex assay (BAMA) were normalized relative to 
the total IgG and IgA measured by ELISA as described (75) 
using plates coated with goat anti-monkey IgG or IgA and the 
secondary antibodies above. 
Plasma S-specific IgG Epitope Mapping 
SARS-CoV-2 antigens, including whole spike (produced by 
PPF), S1 (Sinobiological cat# 40591-V08H), S2 (Sinobiological 
cat# 40590-V08B), RBD (Sinobiological cat# 40592-V08H) 
and NTD (Sinobiological cat# 40591-V49H) were conjugated 
to Magplex beads (Bio-Rad, Hercules, CA). The conjugated 
beads were incubated on filter plates (Millipore, Stafford, VA) 
for 30 min before plasma samples were added. Plasma sam-
ples were diluted in assay diluent (1% dry milk, 5% goat se-
rum, and 0.05% Tween 20 in 1× phosphate buffered saline, 
pH 7.4.) at a 1:10,000-point dilution. Beads and diluted sam-
ples were incubated for 30 min with gentle rotation, and IgG 
binding was detected using a phycoerythrin (PE)-conjugated 
mouse anti-monkey IgG (Southern Biotech, Birmingham, Al-
abama) at 2 μg/ml. Plates were washed and acquired on a Bio-
Plex 200 instrument (Bio-Rad, Hercules, CA), and IgG bind-
ing was reported as mean fluorescence intensity (MFI). To 
assess assay background, the MFIs of wells without sample 
(blank wells) were used, as well as evaluated nonspecific 
binding of the samples to unconjugated blank beads. 
RBD-ACE2 Blocking Assay 
Corning 384-well plates were coated with 3.5 ug/mL ACE2 
protein (Sinobiological) 24 hours before conducting the ex-
periment. The day of the assay, the plate was blocked with 
assay diluent (phosphate-buffered saline containing 4% 
whey, 15% normal goat serum, and 0.5% Tween 20) for 1 hour 
at room temperature. Plasma was diluted 1:10, 1:40, or 1:60 
using the assay diluent, and incubated with 1 ug/mL HRP-
RBD protein (Genescript) at 37C for 1 hour. Plates were 
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washed and the preincubated mixture of plasma and HRP-
RBD protein was added in duplicates and incubated at RT for 
1 hour. Then, plates were washed 4 times to remove unbound 
sample, and peroxidase substrate solution (SeraCare) was 
added for 4 min before stopping the reaction using stop solu-
tion (SeraCare). Signal was detected using a Spectramax plate 
reader at OD 450. The amount of signal detected in wells 
without sample (diluent only) was considered the maximal 
binding response, and the OD450 detected in the sample 
wells was transformed to percentage inhibition compared to 
maximum binding. Data presented is the average of two rep-
licates when CV is less than 20%, and if different assays were 
performed, median value was considered. 
Pseudovirus Antibody Neutralization Assay 
SARS-CoV-2 neutralization was assessed with Spike-
pseudotyped viruses in 293T/ACE2 cells as a function of re-
ductions in luciferase (Luc) reporter activity. 293T/ACE2 cells 
were kindly provided by Drs. Farzan and Mu at Scripps Flor-
ida. Cells were maintained in DMEM containing 10% FBS, 25 
mM HEPES, 50 μg/ml gentamycin and 3 μg/ml puromycin.
An expression plasmid encoding codon-optimized full-length 
Spike of the Wuhan-1 strain (VRC7480), was provided by Drs. 
Graham and Corbett at the Vaccine Research Center, Na-
tional Institutes of Health (USA). The D614G amino acid 
change was introduced into VRC7480 by site-directed muta-
genesis using the QuikChange Lightning Site-Directed Muta-
genesis Kit from Agilent Technologies (Catalog # 210518). The 
mutation was confirmed by full-length Spike gene sequenc-
ing. Pseudovirions were produced in HEK 293T/17 cells 
(ATCC cat. no. CRL-11268) by transfection using Fugene 6 
(Promega Cat#E2692) and a combination of Spike plasmid, 
lentiviral backbone plasmid (pCMV ΔR8.2) and firefly Luc re-
porter gene plasmid (pHR' CMV Luc) (78) in a 1:17:17 ratio. 
Transfections were allowed to proceed for 16-20 hours at 
37oC. Medium was removed, monolayers rinsed with growth 
medium, and 15 ml of fresh growth medium added. Pseudo-
virus-containing culture medium was collected after an addi-
tional 2 days of incubation and was clarified of cells by low-
speed centrifugation and 0.45 μm micron filtration and
stored in aliquots at -80°C. TCID50 assays were performed on 
thawed aliquots to determine the infectious dose for neutral-
ization assays. 
For neutralization, a pre-titrated dose of pseudovirus was 
incubated with 8 serial 5-fold dilutions of serum samples in 
duplicate in a total volume of 150 μl for 1 hour at 37oC in 96-
well flat-bottom poly-L-lysine-coated culture plates (Corning 
Biocoat). Cells were suspended using TrypLE Select Enzyme 
solution (Thermo Fisher Scientific) and immediately added 
to all wells (10,000 cells in 100 μL of growth medium per
well). One set of 8 control wells received cells + virus (virus 
control) and another set of 8 wells received cells only (back-
ground control). After 66-72 hours of incubation, medium 
was removed by gentle aspiration and 30 μL of Promega 1X
lysis buffer was added to all wells. After a 10-min incubation 
at room temperature, 100 μl of Bright-Glo luciferase reagent
was added to all wells. After 1-2 min, 110 μl of the cell lysate
was transferred to a black/white plate (Perkin-Elmer). Lumi-
nescence was measured using a PerkinElmer Life Sciences, 
Model Victor2 luminometer. Neutralization titers are the se-
rum dilution at which relative luminescence units (RLU) 
were reduced by either 50% (ID50) or 80% (ID80) compared to 
virus control wells after subtraction of background RLUs. Se-
rum samples were heat-inactivated for 30 min at 56C prior to 
assay. 
Whole Virus Neutralization Assay 
Neutralization of SARS-CoV-2 nanoLUC carrying the 
D614G mutation was assessed as described in Hou et al. with 
modifications (79). Briefly, under BSL-3 containment, serially 
diluted sera at 8 dilutions were incubated for one hour with 
SARS-CoV-2 D614G nanoLUC virus at 5% CO2 and 37°C. After 
incubation, the virus/antibody mixtures were added in dupli-
cate to black 96-well plates containing Vero E6 cells (2x104 
cells/well). Each plate contains virus-only (no serum) control 
wells. The plates were incubated for 24 hours at 37°C, 5% CO2, 
the cells lysed, and luciferase activity measured with the 
Nano-Glo Luciferase Assay System (Promega). Neutralization 
activity is expressed as the dilution concentration at which 
the observed relative light units (RLU) are reduced by 50% or 
80% relative to virus-only control wells. 
Preparation of S-specific Hook Reagents for Flow Cy-
tometry 
To express the prefusion S ectodomain, a gene encoding 
residues 1−1208 of 2019-nCoV S (GenBank: MN908947) with 
proline substitutions at residues 986 and 987, a “GSAS” sub-
stitution at the furin cleavage site (residues 682–685), a C-
terminal T4 fibritin trimerization motif, an HRV3C protease 
cleavage site, a TwinStrepTag and an 8XHisTag was synthe-
sized and cloned into the mammalian expression vector pαH.
To express the 2019-nCoV RBD-SD1, residues 319−591 of 
2019-nCoV S were cloned upstream of a C-terminal HRV3C 
protease cleavage site, a monomeric Fc tag and an 8XHisTag. 
Similarly, to express the SARS-CoV RBD-SD1, residues 
306−577 of SARS-CoV S (Tor2 strain) were cloned upstream 
of a C-terminal HRV3C protease cleavage site, a monomeric 
Fc tag and an 8XHisTag. Dimers are prepared based on the 
molar ratio (2:1) of the analyte protein and fluorochrome-
conjugated Strep-Tactin, respectively. PE (IBA GmbH, 6-
5000-001) or APC (IBA GmbH, 6-5010-001) conjugated Strep-
Tactin was reacted with the protein over 5 additions, incubat-
ing for 15 min between each addition. The final concentration 
of tetramer was calculated with respect to the analyte pro-
tein. The solution was aliquoted based on the expected usage 
per experiment, snap frozen, and stored at -80°C. For quality 
control, monoclonal antibodies were bound to polystyrene 
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beads (Spherotech) per the manufacturer’s instructions. B 
cell hooks were tested on beads coated with Ab026204 and 
CH65; mAb Ab026204 binds SARS-CoV2, mAb CH65 binds 
influenza hemagglutinin (80) and was used a negative con-
trol. Briefly, 0.5 μL of beads were diluted to 25 μL in
PBS+0.02% NaN3. The bead mixture was added to 6 wells (25 
μL per well) in a 96-well filter plate. B cell hooks were diluted
to a final concentration of 40 μg/mL in 175 μL of PBS+0.02%
NaN3, then four serial 2-fold dilutions were made down to a 
final concentration of 5 μg/mL. Test conjugate dilutions (25
μL per well) were added to each bead set, with one additional
well of each bead set left as an unstained control. After 30-
min incubation, the solution was vacuumed off and the beads 
washed 3 times with 150 μL PBS+0.02% NaN3. The washed
beads were resuspended in 125 μL of PBS+0.02% NaN3, and
the samples were run on a BD LSRII cytometer within 4 
hours of preparation. Data were analyzed using Flow Jo soft-
ware (Treestar) and plots of each dilution compared to the 
unstained control. 
Antigen-specific B Cell Quantitation 
S-specific B cells were assessed by flow cytometry as de-
scribed (39) (Table S1). Freshly isolated or archived (week 6) 
PBMC or LNC (2x106 cells) were washed with phosphate buff-
ered saline (PBS, Gibco) and pelleted by centrifugation at 500 
× g for 7 min. Cells were resuspended in 150 μL 1% bovine
serum albumin (BSA, Sigma-Aldrich) + 5 μM Chk2 inhibitor
II in PBS and incubated 15 min at 4C in the dark, and subse-
quently washed with PBS + 1% BSA (7 min at 500 × g). The 
cell pellet was stained with antibodies prescribed in Table S2 
for 30 min in the dark at 4C. Total CD20+ and/or memory 
CD27+ S-specific B cells were identified as double-positive for 
biotinylated S-2P protein labeled with avidin-APC or avidin-
PE (Fig. S14). Germinal center (GC) B cells were analyzed by 
flow cytometry (Table S2) as detailed elsewhere (81). After 
staining, cells were washed as before and fixed with 1% para-
formaldehyde before immediate acquisition on an LSRFor-
tessa (BD) using BD FACSDiva v.8.0 and analyzed with 
FlowJo software v10.7.1 (Fig. S15). 
B Cell ELISpot 
Polyvinylidene fluoride membranes (Millipore) were acti-
vated with 70% ethanol for 1 min, subsequently coated with 1 
μg SARS-CoV-2 Spike protein (2019-nCoV) per well and
blocked for 2 hours with 2% milk and stored at 4C. Fresh or 
thawed cell preparations were washed and stimulated (106 
cells/mL) with 1 μg/mL R848 (InvivoGen, San Diego, CA) and
10 ng/mL human IL‐2 (Miltenyi Biotec) for 72 hours in com-
plete medium (cRPMI): RPMI‐1640 medium (Gibco) contain-
ing penicillin, streptomycin, L‐glutamine (Sigma‐Aldrich), 
and 10% heat‐inactivated FBS (Gibco). Stimulated cells (8 × 
104/well) were incubated in triplicate wells of SARS-CoV-2 
Spike protein-coated microtiter plates overnight at 37°C, 
washed with PBS+0.05% Tween 20, and incubated 1 hour 
with 1 μg/mL biotinylated affinity‐purified goat anti‐human
IgG (Southern Biotech) at room temperature. Plates were 
washed with PBS+0.05% Tween 20, incubated with a 1:4000 
dilution of avidin‐peroxidase (Southern Biotech) for 1 hour at 
room temperature, and developed using the BD AEC kit using 
100 μL per well. Dried membranes were analyzed with an au-
tomated ELISpot Reader System (Autoimmun Diagnostika 
GmbH). Results are reported as the number of antibody‐se-
creting cells (ASC) per 106 MNCs. 
T Cell Responses 
Cryopreserved cells were thawed, or fresh preparations 
were washed and cultured in cRPMI (106/mL) with or with-
out 2 μg/mL overlapping peptides spanning the length of
SARS-CoV-2 spike protein (JPT Technologies) or DMSO vehi-
cle together with co-stimulatory antibodies against CD28 and 
CD49d from BD. Naïve donor cells were included with each 
assay and, in addition to peptide pool or vehicle, were stimu-
lated with 0.5x cell stimulation cocktail (eBiosciences) as a 
positive control. Cells were surface stained as outlined in Ta-
ble S2 and then permeabilized with BD CytoFix/CytoPerm 
per manufacturer’s recommendations and stained with intra-
cellular antibodies as prescribed in Table S2. Data were col-
lected using an LSRFortessa and BD FACSDiva v8.0 and 
analyzed with FlowJo software v10.7.1 (TreeStar). Intracellu-
lar cytokine gates (Fig. S16) were Boolean gated and reported 
as single positive events unless otherwise noted. 
In addition, we performed the activation-induced marker 
(AIM) assay (49, 82) on cryopreserved LNC. Cells were 
thawed, rested 3 h at 37°C with 5% CO2, resuspended in AIM 
V medium (Gibco), and transferred at 106 cells per well to a 
24-well plate. Cells were cultured with vehicle DMSO (nega-
tive control) or with 0.5 μg/ml staphylococcal enterotoxin B
(Toxin Technologies) for 20 hours at 37°C with 5% CO2. After
stimulation, cells were stained with prescribed antibodies per
Table S2 and acquired immediately on an LSRFortessa in-
strument running FACSDiva v8.0 software (BD Biosciences)
and analyzed as described above (see Fig. S17).
Plasma Cytokine Measurements 
IL-2, IL-4, IL-13, and IFN-γ in undiluted plasma samples
were quantified by a custom 4-plex rhesus macaque Luminex 
assay (Thermofisher Scientific) using protocols established 
by the supplier. ELISA results are reported as the average 
concentration of duplicate wells extrapolated from a stand-
ard curve. 
Statistical Analyses 
Spearman’s rank correlations were estimated between 
pre-specified parameters at specific timepoints. Statistical 
analyses were performed using SAS version 9.4 (Cary, NC, 
USA). ID50 neutralization titer decline half-life was esti-
mated based on random-effects regression models of decay 
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with first-order kinetics (83, 84). Models were fit separately 
by vaccine group and data prior to the second vaccine dose 
(i.e., from weeks 0 and 4) were excluded. Bi-phasic decline 
was modeled using a linear spline with one knot (85), with 
different knots considered ranging from 8 to 18 weeks. For 
each vaccine group, the model with the knot at 18 weeks fit 
the best according to the Akaike Information Criterion. 
SUPPLEMENTARY MATERIALS 
immunology.sciencemag.org/cgi/content/full/6/60/eabj3684/DC1 
Figs. S1 to S17 
Tables S1 to S3 
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Fig. 1. Study Design: evaluation of immunogenicity of two SARS-CoV-2 vaccines in infant 
rhesus macaques. Infant rhesus macaques (median age of 2.2 months at study initiation) were 
immunized at 0 and 4 weeks with either 30 μg mRNA encoding S-2P (Vaccine Research Center, 
NIH) in lipid nanoparticles (mRNA-LNP) or 15 μg S-2P protein formulated with 3M-052 adjuvant, 
a TLR7/8 agonist, as a stable emulsion (3M-052-SE). Each group consisted of 8 animals. Blood 
and saliva samples were collected at weeks 0, 4, 6, 8, 14, 18 and 22, and lymph node biopsies 
were obtained at week 6. 
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Fig. 2. SARS-CoV-2 vaccine-elicited binding antibody responses in infant rhesus macaques. Plasma and saliva were 
collected before vaccination (week 0), at week 4 - prior to the 2nd dose-, two weeks post 2nd dose (week 6), and at weeks 8, 
14, 18 and 22 from infant RM vaccinated with 30 μg mRNA encoding S-2P spike protein in lipid nanoparticles (n=8; red) or 
with 15 μg prefusion SARS-CoV-2 S-2P spike protein formulated with 3M-052 adjuvant (n=8; blue). (A): S-2P protein-specific 
antibody responses were measured by enzyme-linked immunosorbent assay (ELISA). Serial dilutions of plasma starting at 
1:40 were assayed for IgG binding to SARS-CoV-2 spike. Data are reported as log10 area under the curve (AUC) values. (B): 
Antibody epitope specificity measured by BAMA. Plasma was diluted 1:10,000 to measure binding to different domains of 
the spike protein, including the full-length S protein, S1, RBD, NTD, and S2. Binding antibody responses are reported as log10 
transformed mean fluorescence intensity (MFI) after subtraction of background values. (C): Salivary RBD-specific IgG was 
measured by binding antigen multiplex assay (BAMA) using serial dilutions of saliva and responses are reported as RBD-
specific IgG (ng) / total IgG (μg). Different symbols represent individual animals (Table 1). Arrows in Panel A indicate times 
of immunizations. 
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Fig. 3. SARS-CoV-2 vaccine-elicited functional antibody responses in infant rhesus macaques. (A): The 
capacity of plasma antibodies to mediate blocking of the RBD-ACE2 interaction was measured with an ELISA-
based ACE2 blocking assay at 1:10 plasma dilution. Data are reported as %ACE2 blocking. (B-C): Neutralization 
capacity was measured using Spike D614G-pseudotyped viruses in 293T/ACE2 cells (B) and whole virus (D614G) 
assay with Vero E6 cells (C); results are expressed as reciprocal 80% inhibitory dilution (ID80). Grey dotted lines 
represent detection cut-off. Different symbols represent individual animals (Table 1). Longitudinal data for each 
animal in the mRNA-LNP (red) or Protein+3M-052-SE group (blue) are represented by separate lines. Arrows in 
Panel C indicate times of immunizations. 
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Fig. 4. Characterization of Spike-specific B cell responses two weeks post boost. (A) CD20+CD27+ memory B cells 
that co-stained with fluorochrome-conjugated SARS-CoV-2 spike protein in mRNA-LNP (red) or Protein+3M-052-SE 
(blue) vaccinees in blood. Frequencies are expressed as percent of total memory B cells. The gating strategy is 
provided in Supplementary Figure S14. (B): In lymph nodes, we determined total Bcl-6+Ki-67+ Germinal Center (GC) 
B cells and CD27+ memory B cells as percent of total CD20+ B cells (left panel) (see Fig. S15 for gating strategy) and 
also the percent of S-specific memory B cells (right panel). (C) Antibody secreting cell (ASC) as measured by B cell 
ELISpot in PBMC from mRNA-LNP or Protein+3M-052-SE vaccinees, while (D) is showing mRNA-LNP and 
Protein+3M-052-SE ASC responses, respectively, in LN at week 6. Different symbols represent individual animals 
(Table 1). Solid lines represent median values. 
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Fig. 5. Immunophenotype of lymph node T cell population two weeks post-boost. (A): CD4+ T-cells positive 
for IL-4 or IL-21, follicular T helper cell (Tfh) markers CD279/PD-1 and CD185/CXCR5, or Bcl6+ Tfh were 
measured and are represented as percent of total LN CD4+ T cells. The gating strategy for these panels is 
provided in Figure S15. (B): SEB activated Tfh frequencies assessed by the Activation-Induced Marker (AIM) 
Assay: CXCR5+CD185+ cells that co-expressed CD134 and CD137 for Protein+3M-052-SE and mRNA-LNP, 
respectively. (C) The frequency of CXCR5+CD185+CD134+CD137+CXCR3+CD196- Tfh1, CXCR3-CCR6- Tfh2 and 
CXCR3-CD196+ Tfh17 cells is shown. The gating strategy for these populations is given in Fig. S17. Red symbols: 
mRNA-LNP, blue symbols: Protein+3M-052-SE. Different symbols represent individual animals (Table 1). Solid 
lines define the median. 
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Fig. 6. Spike-specific CD4+ T cell responses in SARS-CoV-2 immunized infant macaques. Intracellular cytokine 
staining for IL-2, IL-17, IFN-γ, and TNF-α (indicated at the x-axis in Panel D) was performed on PBMC at weeks 4 (A), 
6 (B), 8 (C), and 14 (D) to assess T-cell responses to a peptide pool encompassing the entire SARS-CoV-2 spike 
protein (see Fig. S16 for gating strategy). Responses detected in mRNA-LNP recipients are displayed in red and 
cytokine responses from Protein+3M-052+SE vaccinees are in blue. The dashed lines represent week 0 values plus 2 
standard deviations and define the cutoff for positive cytokine responses. Different symbols represent individual 
animals (Table 1). 
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Table 1. Overview of study animals. 




RM 1 male 2.6 filled circle 
RM 2 female 2.4 open circle 
RM 3 male 2.3 filled triangle 
RM 4 female 2.3 open triangle 
RM 5 female 2.2 open inverted triangle 
RM 6 male 2.1 filled inverted triangle 
RM 7 female 2.0 open diamond 
RM 8 male 1.6 filled diamond 
mRNA-LNP red: 
RM 9 female 2.5 open circle 
RM 10 male 2.4 filled circle 
RM 11 male 2.4 filled triangle 
RM 12 female 2.3 open triangle 
RM 13 male 2.2 filled inverted triangle 
RM 14 female 2.1 open inverted triangle 
RM 15 male 2.1 filled diamond 
RM 16 female 2.1 open diamond 
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sponses Pseudovirusc Live Virus 
Current Infant NHP Study 
(30 μg)
4 weeks post 2nd dose AUC (log10): 7.0 
GMT: 55,564 
ID50: 3,174 ID50: 12,068 TH1; 
IL-21+ TH 
10 weeks post 2nd dose AUC (log10): 6.2 
GMT: 19,054 
ID50: 1,199 ID50: 1,379 
Adult NHP 
Corbett et al., N Engl J Med. 2020; 383(16):1544-1555 
4 weeks post 2nd dose 
10 μg AUC: 8,421d ID50: 103d ID50: 501d,e TH1>TH2; 
IL-21+ TFH 100 μg AUC: 36,186d ID50: 1,862d ID50: 3,481 d,e 
Corbett et al., bioRxiv;doi.org/10.1101/2021.04.20.440647 
4 weeks post 2nd dose 
30 μg GMT: 64,000f ID50: ~103 f TH1>TH2; 
IL-21+ TFH 
Human Adults (18-55 years) 
Jackson et. al 
N Engl J Med. 2020; 383(20):1920-1931. 
4 weeks post 2nd dose 
10 μg GMT: 299,751 d ID50: 81 d 
100 μg GMT: 782,719 d ID50: 232 d 
250 μg GMT: 1,192,154 d ID50: 270 d 
2 weeks post 2nd dose 
10 μg GMT: 379,764 d ID50: 112 d ID80: 340 d,g 
100 μg GMT: 811,119 d ID50: 344 d ID80: 654 d.g 
250 μg GMT: 994,629 d ID50: 332 d no data 
Anderson et al., N Engl J Med. 2020; 383(25): 2427-2438. 
4 weeks post 2nd dose 
25 μg GMT: 323,945 d 
100 μg GMT: 1,183,066 d ID50: 402 d ID50: 878 d,e TH1>TH2 
Widge et al., N Engl J Med. 2021; 384(1):80-82. 
3 months post 2nd dose 
100 μg GMT: 235,228f ID50: 182 g ID50: 775 g, e 
a Study listed with reference, time of immune analysis for reported data, and vaccine dose 
b Plasma Binding IgG levels against spike protein are reported as area under the curve (AUC) or 
geometric mean titers (GMT). Note that the SARS-CoV-2 strain from which the spike antigen 
for the assay was derived is listed under each study. 
c Lentiviral-based pseudovirus neutralization (PsVNA) 
d Wuhan.Hu.1 spike protein 
e Focus reduction neutralization test (FRNT) 
f D614G spike protein 
g SARS-CoV-2 Plaque-reduction neutralization testing (PRNT) 
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